This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Dividendos de Reata Pharmaceuticals

Dividendo controles de criterios 0/6

Reata Pharmaceuticals does not have a record of paying a dividend.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.3%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$2.30
Rentabilidad por dividendo prevista a 3 años	0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

May 10

FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug

Oct 13

Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?

Oct 12

Reata Pharmaceuticals Q2 2022 Earnings Preview

Aug 05

We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth

Jun 22

Reata Pharmaceuticals: Once Beaten, Twice Shy

Mar 28

Reata's Advisory Committee Hiccup Ruins Its Future Prospects

Dec 31

Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

Dec 23

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: Insufficient data to determine if RETA's dividends per share have been stable in the past.

Dividendo creciente: Insufficient data to determine if RETA's dividend payments have been increasing.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Reata Pharmaceuticals vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de RETA con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (RETA)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.6%
Media de la industria (Pharmaceuticals)	2.3%
Previsión de analistas en 3 años (RETA)	0%

Dividendo destacado: Unable to evaluate RETA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Alto dividendo: Unable to evaluate RETA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Pago de beneficios a los accionistas

Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: Unable to calculate sustainability of dividends as RETA has not reported any payouts.

This company has been acquired

Dividendos de Reata Pharmaceuticals

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from NASDAQ Composite Index

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Insider recently sold US$546k worth of stock

Insider notifies of intention to sell stock

Executive VP & Chief Innovation Officer recently sold US$463k worth of stock

Sanofi Reportedly Second Bidder for Reata

Consensus revenue estimates increase by 60%

Consensus revenue estimates increase by 67%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

COO, CFO & President notifies of intention to sell stock

New major risk - Share price stability

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Price target increased by 8.5% to US$125

Reata Pharmaceuticals, Inc. Announces Approval of Prior Approval Supplement for SKYCLARYS®? (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's Ataxia

Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from Russell 2000 Growth Index

COO, CFO & President recently sold US$6.0m worth of stock

COO, CFO & President notifies of intention to sell stock

Reata Pharmaceuticals Appoints Rajiv Patni as Executive Vice President, Chief Research & Development Officer

Insider recently sold US$616k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Forecast to breakeven in 2025

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

Executive VP & Chief Commercial Officer recently sold US$808k worth of stock

Executive VP & Chief Commercial Officer recently sold US$630k worth of stock

Executive VP & Chief Innovation Officer exercised options and sold US$7.7m worth of stock

Forecast to breakeven in 2025

Consensus revenue estimates increase by 18%, EPS downgraded

Price target increased by 75% to US$104

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$59.50

Consensus forecasts updated

Price target increased to US$59.50

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Reata Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug

Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?

Consensus forecasts updated

Price target decreased to US$50.67

Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Reata Pharmaceuticals Q2 2022 Earnings Preview

Reata Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Reata Pharmaceuticals, Inc. Announces the Appointment of Steven W. Ryder, M.D. to Board of Directors

We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth

Reata Pharmaceuticals, Inc. Announces Retirement of Jack B. Nielsen from Board of Directors

Reata Pharmaceuticals Announces U.S. Food and Drug Administration Filing Acceptance

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Reata Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Reata Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2022

Price target increased to US$59.67

Reata Pharmaceuticals Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia

Reata Pharmaceuticals: Once Beaten, Twice Shy

Price target increased to US$62.75

Reata Pharmaceuticals, Inc. Notifies Jack B. Nielsen's Intention to Retire from the Board

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Reata Pharmaceuticals Receives Complete Response Letter from the FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

Reata Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Reata Pharmaceuticals, Inc. Announces Executive Changes

Pomerantz LLP Files Class Action Lawsuit Against Reata Pharmaceuticals, Inc

Block & Leviton LLP Files Class Action Lawsuit Against Reata Pharmaceuticals, Inc. for Securities Fraud, Expanding the Class Period

Reata's Advisory Committee Hiccup Ruins Its Future Prospects

Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies